Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade

Patients suffering from recurrent or metastatic (R/M) salivary duct carcinoma (SDC) are often treated with combined androgen blockade (CAB). However, CAB frequently fails, resulting in a worse prognosis. Therefore, biomarkers that can predict treatment failure are urgently needed. mRNA from 76 R/M a...

Full description

Bibliographic Details
Main Authors: Gerben Lassche, Yuichiro Tada, Carla M. L. van Herpen, Marianne A. Jonker, Toshitaka Nagao, Takashi Saotome, Hideaki Hirai, Natsuki Saigusa, Hideaki Takahashi, Hiroya Ojiri, Adriana C. H. van Engen-Van Grunsven, Jack A. Schalken, Chihiro Fushimi, Gerald W. Verhaegh
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
salivary gland neoplasms (MesH)
androgen antagonists (MesH)
salivary duct carcinoma
androgen deprivation therapy
biomarkers (MesH)
Online Access:https://www.mdpi.com/2072-6694/13/14/3527

Internet

https://www.mdpi.com/2072-6694/13/14/3527

Similar Items